Lv6
2335 积分 2022-04-04 加入
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
20小时前
待确认
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
21小时前
待确认
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
21小时前
待确认
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
21小时前
待确认
Sorafenib in Advanced Hepatocellular Carcinoma
21小时前
待确认
Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment
1天前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
1天前
已完结
Hepatocellular Carcinoma
1天前
已完结
Disparities in stage at diagnosis for liver cancer in China
1天前
已完结
Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries
1天前
已完结
皖公网安备34019202002308
